Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+

被引：66

作者：

Safaian, N. N. ^{[1
]}

Czibere, A. ^{[1
]}

Bruns, I. ^{[1
]}

Fenk, R. ^{[1
]}

Reinecke, P. ^{[2
]}

Dienst, A. ^{[1
]}

Haas, R. ^{[1
]}

Kobbe, G. ^{[1
]}

机构：

[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany

[2] Univ Dusseldorf, Dept Pathol, Dusseldorf, Germany

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 02期

关键词：

AML; Sorafenib; Chloroma; FLT3; ANTITUMOR-ACTIVITY; APOPTOSIS; CELLS;

D O I：

10.1016/j.leukres.2008.04.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The fins-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) can he found in about one quarter of patients with acute myeloid leukemia (AML) [Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematology. Educ. Program 2006; 178-84 [Review]]. Patients who carry this Mutation have a high risk of relapse even after allogeneic stern cell transplantation [Sheikhha MH. A, van A, Tobal K. Liu Yin JA. Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Hematol J 2003;4;41-6: Meshinchi S. Arceci RJ, sanders JE, Smith FO. Woods WB. Radich JP, et al. Role of allogeneic stern cell transplantation in FLT3/ITD-positive AML. Blood 2006;108(1):400-1]. Recent reports show that Sorafenib. a multikinase inhibitor has significant activity against FLT3-ITD+ blasts in vitro [Auclair D, Miller D. Yatsula V. Pickett W, Carter C. Chang Y, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007 21(3):439-45]. We here report the first Clinical case of Molecular remission induced by Sorafenib in a patient with FLT3-ITD+ AML and extramedullary disease after allogenic stern cell transplantation. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：348 / 350

页数：3

共 5 条

[1] Antitumor activity of sorafenib in FLT3-driven leukemic cells [J].

Auclair, D. ;

Miller, D. ;

Yatsula, V. ;

Pickett, W. ;

Carter, C. ;

Chang, Y. ;

Zhang, X. ;

Wilkie, D. ;

Burd, A. ;

Shi, H. ;

Rocks, S. ;

Gedrich, R. ;

Abriola, L. ;

Vasavada, H. ;

Lynch, M. ;

Dumas, J. ;

Trail, P. A. ;

Wilhelm, S. M. .

LEUKEMIA, 2007, 21 (03) :439-445

[2] Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [J].

Liu, Li ;

Cao, Yichen ;

Chen, Charles ;

Zhang, Xiaomei ;

McNabola, Angela ;

Wilkie, Dean ;

Wilhelm, Scott ;

Lynch, Mark ;

Carter, Christopher .

CANCER RESEARCH, 2006, 66 (24) :11851-11858

[3] RETRACTED: The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells (Retracted article. See vol. 79, pg. 5459, 2019) [J].

Panka, DJ ;

Wang, W ;

Atkins, MB ;

Mier, JW .

CANCER RESEARCH, 2006, 66 (03) :1611-1619

[4] Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib [J].

Ranze, Oliver ;

Hofmann, Erich ;

Distelrath, Andrea ;

Hoeffkes, Heinz-Gert .

ONKOLOGIE, 2007, 30 (8-9) :450-451

[5] Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors [J].

Strumberg, Dirk ;

Clark, Jeffrey W. ;

Awada, Ahmad ;

Moore, Malcolm J. ;

Richly, Heike ;

Hendlisz, Alain ;

Hirte, Hal W. ;

Eder, Joseph P. ;

Lenz, Heinz-Josef ;

Schwartz, Brian .

ONCOLOGIST, 2007, 12 (04) :426-437

← 1 →